AI-Based Digital Pathology Model for Predicting Treatment Response and Prognosis in mHSPC
NCT07924644, Not applicable, Active not recruiting, Xiangya Hospital of Central South University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | AI-Based Digital Pathology Model for Predicting Treatment Response and Prognosis in mHSPC | ClinicalTrials.gov |
| NCT number | NCT07924644 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 1,115 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Xiangya Hospital of Central South University | ClinicalTrials.gov |
| Conditions | Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer) | ClinicalTrials.gov |
| Interventions | Artificial Intelligence-Based Digital Pathology Assessment | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Predictive Performance of the AI-Based Digital Pathology Model for Deep PSA Response | 6 to 7 months after initiation of ADT plus ARSI | The primary outcome measure is the area under the receiver operating characteristic curve of the artificial intelligence-based digital pathology model for predicting deep prostate-specific antigen response. Deep PSA response is defined as a prostate-specific antigen level of less than 0.2 ng/mL at 6 to 7 months after initiation of androgen deprivation therapy plus androgen receptor signaling inhibitors. Model performance will be evaluated in the validation cohort. | ClinicalTrials.gov |
| Secondary | Concordance Index of the Artificial Intelligence-Based Digital Pathology Model for Predicting Metastatic Castration-Resistant Prostate Cancer | Up to 60 months after initiation of androgen deprivation therapy plus androgen receptor signaling inhibitors. | The secondary outcome measure is the concordance index of the artificial intelligence-based digital pathology model for predicting time to metastatic castration-resistant prostate cancer. Time to metastatic castration-resistant prostate cancer is defined as the interval from initiation of androgen deprivation therapy plus androgen receptor signaling inhibitors to the development of metastatic castration-resistant prostate cancer. Patients without metastatic castration-resistant prostate cancer at the last follow-up will be censored. Model performance will be evaluated in the validation cohort. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)